US Patent Reform: Implications for Indian Pharma
CH Unni of the Mint reported sometime back on the US patent reform and how it was likely to impact Indian pharma companies. He notes in particular that: “Indian pharmaceutical firms, which make most of their revenues and profits from the manufacture of off-patent, or generic, drugs, are set to play a larger role in the US, the world’s biggest drug market. That is, if a US plan to reform patent laws by including provisions for what is called post-grant […]
US Patent Reform: Implications for Indian Pharma Read More »

